DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
- DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
- The leading Glioblastoma Companies working in the market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
- Promising Glioblastoma Pipeline Therapies in the various stages of development include Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
- January 2024: Hoffmann-La Roche announced a study of Phase 1 clinical trials for RO7428731. This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).
- December 2023: Boehringer Ingelheim announced a study of Phase 1 clinical trials for BI 907828 (Brigimadlin). This study is open to adults with newly diagnosed glioblastoma, a type of brain tumor. The study has two parts. Part 1 is open to people who can get their brain tumor removed by surgery. Part 2 is open to people who already had such a brain surgery.
- December 2023: Eli Lilly and Company announced a study of Phase 2 clinical trials for LY2157299 monohydrate, and Lomustine. The purpose of the study is to see whether treatment with LY2157299 on its own, LY2157299 plus lomustine therapy or lomustine plus placebo can help participants with brain cancer.
- December 2023: Cantex Pharmaceuticals announced a study of Phase 2 clinical trials for Azeliragon. This is a phase 2 study to evaluate the safety and preliminary evidence of effectiveness of azeliragon, in combination with radiation therapy, as an initial treatment of a form of glioblastoma. Glioblastoma is a type of brain cancer that grows quickly and can invade and destroy healthy tissue. There’s no cure for glioblastoma, which is also known as glioblastoma multiforme.
- December 2023: Enterome announced a study of Phase 1 & 2 clinical trials for Multiple dose of EO2401. The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
Request a sample and discover the recent advances in Glioblastoma Drugs @ Glioblastoma Pipeline Outlook Report
In the Glioblastoma Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details. The assessment part of the report embraces, in depth Glioblastoma commercial assessment and clinical assessment of the Glioblastoma pipeline products under development.
Glioblastoma Overview
The glioblastoma multiforme preferentially invades along myelinated axons, vascular basement membranes, and the subependyma, mostly occurring in the subcortical matter of the cerebrum (65%). Within the cerebrum, the tumors proliferate through the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes. However, tumor formation is rarely isolated exclusively to one of these lobes, instead presenting in a combination of these lobes within the cerebrum. GBM also forms in the hypothalamus-thalamus area (20%) and the cerebellum and posterior fossa (15%).
Find out more about Glioblastoma Analysis @ Glioblastoma Drugs
Glioblastoma Emerging Drugs Profile
- Enzastaurin: Denovo BioPharma
- Tofacitinib: Pfizer
- VT1021: Vigeo Therapeutics
- Varlilumab: Celldex Therapeutics
- Debio 0123: Debiopharm
- PRT3645: Prelude Therapeutics
Glioblastoma Therapeutics Assessment
There are approx. 195+ Glioblastoma companies which are developing the therapies for Glioblastoma. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma. The Glioblastoma pipeline report proffers an integral view of the emerging Glioblastoma segmented by stage, product type, molecule type, and route of administration.
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Dive deep into rich insights for new Glioblastoma, visit @ Glioblastoma Treatment Landscape
Glioblastoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Scope of the Glioblastoma Pipeline Report
- Coverage- Global
- Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
- Glioblastoma Pipeline Therapies- Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, LAM561, Onfekafusp Alfa, and others.
For further information on the Glioblastoma Pipeline Therapeutics, reach out @ Glioblastoma Therapeutics Segmentation
Table of Content
- Introduction
- Glioblastoma Executive Summary
- Glioblastoma: Overview
- Glioblastoma Pipeline Therapeutics
- Glioblastoma Therapeutic Assessment
- Glioblastoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Enzastaurin: Denovo BioPharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Varlilumab: Celldex Therapeutics
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PRT3645: Prelude Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- ELC-401: Elicera Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Glioblastoma Key Companies
- Glioblastoma Key Products
- Glioblastoma- Unmet Needs
- Glioblastoma- Market Drivers and Barriers
- Glioblastoma- Future Perspectives and Conclusion
- Glioblastoma Analyst Views
- Glioblastoma Key Companies
- Appendix
Find out more about Glioblastoma Therapeutics Assessment @ Glioblastoma Preclinical and Discovery Stage Products
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/mouth-neoplasms-market